References


Pyridoxine (vitamin B6) therapy for premenstrual syndrome

M. Kashanian a,⁎, R. Mazinani b, S. Jalalmanesh c

a Department of Obstetrics and Gynecology, Akbarabadi Teaching Hospital, Iran University of Medical Sciences, Tehran, Iran
b Department of Psychiatry, University of Welfare and Rehabilitation Sciences, Tehran, Iran
c Department of Midwifery, Iran University of Medical Sciences, Tehran, Iran

Received 7 July 2006; received in revised form 5 September 2006; accepted 12 September 2006

KEYWORDS

Placebo; Premenstrual syndrome; Psychiatric symptoms; Pyridoxine hydrochloride; Somatic symptoms; Vitamin B6

Pyridoxine and placebo tablets were manufactured by the same factory and had the same shape, color, and taste. The recording sheet included the 17 symptoms (11 behavioral and 6 somatic) listed in the American Psychiatric Association (APA) questionnaire [2]. For the diagnosis of PMS, at least 1 behavioral and 1 somatic symptom were necessary. After the first 3 cycles of simply recording their symptoms, the participants took a daily tablet containing either 80 mg of pyridoxine or placebo from the first day of the fourth cycle through the next 2 cycles. During this period, they continued to record their symptoms on the recording sheet. The drug’s efficacy was judged in the second cycle of use.

There were no statistically significant differences between the 2 groups regarding the number of symptoms and severity of PMS. The most prevalent symptoms in both the pyridoxine group and placebo group were irritability (87%) and depression (87.5%). The symptoms of moodiness, irritability, anxiety, depression, forgetfulness, unreasonable crying (shedding tears), dizziness, fatigueability, candy craving, increased appetite, palpitations, breast tenderness, bloating, and edema significantly decreased after treatment with pyridoxine, and among these symptoms anxiety showed the greatest reduction (mean±SD reduction, −0.22±0.35). In the placebo group the

Figure 1 Receiver-operating characteristic (ROC) curve for the evaluation of CA-125 concentration, RMI, and Ferrazzi score in predicting ovarian malignancy in premenopausal women referred for endoscopic management of adnexal masses.
symptoms of moodiness, anxiety, depression, unreasonable crying, fatigability, increased appetite, palpitations, and bloating showed a significant decrease, with anxiety showing the greatest reduction ($-0.15 \pm 0.35$). A comparison between the severity of psychiatric symptoms after treatment with pyridoxine and placebo showed a significant decrease following the 2 forms of treatment (paired t test, $P < 0.05$), but the reduction was significantly greater in the pyridoxine group (Table 1).

The comparison between the severity of somatic symptoms after and before treatment with pyridoxine and placebo showed a significant reduction after both forms of treatment (paired t test, $P < 0.05$), but there was no significant difference between the 2 groups (Table 1).

Finally, there was a significant reduction in PMS severity following both forms of treatment (paired t test, $P < 0.05$), and a comparison between the 2 groups also showed a significantly greater reduction in the pyridoxine group than in the placebo group ($P < 0.05$, t test).

In conclusion, as a follow-up on the several studies [3,4] undertaken on the effect of pyridoxine on the symptoms of PMS, pyridoxine can be suggested as a treatment for PMS, at least for the psychiatric symptoms.

References

Table 1 Total score changes in women with premenstrual syndrome (PMS) treated with pyridoxine or placebo

<table>
<thead>
<tr>
<th></th>
<th>Pyridoxine group</th>
<th>$P$ value (paired t test)</th>
<th>Placebo group</th>
<th>$P$ value (paired t test)</th>
<th>$P$ value (t test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total psychiatric score change</td>
<td>$-1.26 \pm 1.91$</td>
<td>$P &lt; 0.05$</td>
<td>$-0.60 \pm 1.78$</td>
<td>$P &lt; 0.05$</td>
<td>$P &lt; 0.05$</td>
</tr>
<tr>
<td>Total somatic score change</td>
<td>$-0.54 \pm 0.63$</td>
<td>$P &lt; 0.05$</td>
<td>$-0.33 \pm 0.70$</td>
<td>$P &lt; 0.05$</td>
<td>NS</td>
</tr>
<tr>
<td>Total PMS score change</td>
<td>$-1.80 \pm 2.36$</td>
<td>$P &lt; 0.05$</td>
<td>$-0.93 \pm 2.33$</td>
<td>$P &lt; 0.05$</td>
<td>$P &lt; 0.05$</td>
</tr>
</tbody>
</table>

Abbreviation: NS, not satisfactory.

Laparoscopic uterine artery occlusion versus uterine fibroid embolization

Z. Holub a,⁎, M. Mara b, J. Eim c

a Department of Obstetrics and Gynecology, Endoscopic Training Center, Baby Friendly Hospital, Kladno, Czech Republic
b Department of Obstetrics and Gynecology, General Faculty Hospital and 1st Medical Faculty of Charles University, Prague, Czech Republic
c Department of Gynecology and Minimally Invasive Surgery, County Hospital, Vyskov, Czech Republic

Received 13 June 2006; received in revised form 24 August 2006; accepted 13 September 2006

KEYWORDS
Fibroid;
Laparoscopy;
Pregnancy;
Uterine artery occlusion;
Uterine embolization

Laparoscopic uterine artery occlusion (LUAO) and uterine artery embolization (UAE) have been shown in several large cohort studies to be effective treatments for symptomatic uterine fibroids [1,2]. Minimal data have been published, however, regarding the effects of LUAO and UAE on fertility and pregnancy [3,4].

Pregnancy outcomes following LUAO and UAE were evaluated in a prospective controlled cohort study conducted in the Czech Republic at 3 endoscopic centers overseen by the Czech Society for Gynecological Endoscopy. In the Kladno and

⁎ Corresponding author. Tel.: +420 312 606 383.
E-mail address: holubz@seznam.cz (Z. Holub).